Expression of Elk-1 in Non-Small Cell Lung Cancer Detected by Western Blot and Tissue Microarray

Objective： The aim of this study was to investigate the Elk-1 （Ets like transcription factor-1） expression in non-small cell lung cancer （NSCLC） and normal lung tissues and the relationship between its expression and clinicopathological characters. Methods： To observe Elk-1 expression, western blot and immunochemistry （IHC） on tissue microarray （TMA） containing 118 lung cancers and their corresponding normal tissues were used. Results： In western blot and IHC on TMA, Elk-1 was highly expressed in NSCLC, while its expression was almost undetectable in normal lung tissues. Elk- 1 expression in NSCLC had no relationship with the patients＇ age, gender, smoking status and histological type, but had relationship with the differentiation degree, clinical stages and lymphonode metastasis. The expression was lower in early stage group （Ⅰ＋Ⅱ） than in advanced stage group （Ⅲ）, and lower in well-moderately differentiated group than in poorly differentiated group. The same trend was seen with lymphonode metastasis. Conclusion： The progression of NSCLC may be related with the increased Elk-1 expression, and Elk-1 may be regarded as a prognostic factor for NSCLC tissues.

Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor -2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer

Background Hypoxia-inducible factor （HIF） may play an important role in the process of tumorigenesis as well as tumor progression. The aim of this study was to compare the expression between HIF-1α and HIF-2α in tumor angiogenesis and the overall impact on patient prognosis in human non-small cell lung cancer （NSCLC）. Methods In the current work we compared the immunohistochemical expression of HIF-1α and HIF-21 in surgical specimens of 140 patients with NSCLC in a tissue microarray study. Relationships between HIF-α expression and clinicopathological or angiogenic factors, including prognosis, were analyzed. Results High HIF-1α and HIF-2α expression was noted in 49/140 （35.0%） and in 64/140 （45.7%） of the cases, respectively. There was no direct correlation between HIF-la and HIF-2α expression. Patients with advanced stage tumors had frequent high expression of HIF-2a （P=0.007）, and we also found a significant correlation between HIF-2α and T or N stage （P=0.030 and 0.043, respectively）. HIF-1α showed a marginal association with T stage （P=0.084）, which showed a higher expression in early stage tumors. A significant correlation （p=0.045） was noticed between HIF-1α and vascular endothelial growth factor （VEGF） expression while the expression levels of thymidine phosphorylase （TP）, cyclooxygenase （COX）-2 and microvessel density （MVD） were significantly higher in high HIF-2a tumors （P=0.020, 0.004 and 0.046, respectively）. In addition, univariate analysis of overall survival demonstrated that HIF-2a expression, but not HIF-la, was related to poor outcome （P=-0.001） and it retained significant in multivariate analysis （P=0.036）. Conclusions Taken together, we conclude that HIF-1α and HIF-2α may differentially regulate the major angiogenic factors in different stages of the tumor process in NSCLC. HIF-2α may play a dominant role in tumor angiogenesis and appears to be of obvious value as a significant prognostic factor in NSCLC.

TK1、Ki-67在非小细胞肺癌组织中的表达及预后意义

目的:探讨细胞质胸苷激酶1(thymidine kinase 1,TK1)和Ki-67在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达水平及其对NSCLC患者预后的意义。方法:将202例NSCLC及63例癌旁肺组织标本制作成组织芯片,采用免疫组织化学EnVision法检测TK1和Ki-67的表达,探讨其表达水平与临床病理特征及预后的关系。结果:NSCLC组织中TK1(60.89%)和Ki-67(55.45%)的阳性表达率均显著高于癌旁肺组织(P<0.01);Spearman等级相关分析显示二者的表达呈正相关(r=0.518,P<0.001);NSCLC中,TK1和Ki-67的表达均与肿瘤分化程度和TNM分期显著相关(P<0.05);Kaplan-Meier生存分析显示随TK1表达的增强和Ki-67指数的增高,NSCLC患者的总体生存期逐渐降低(P<0.01);Cox回归分析提示肿瘤TK1表达和TNM分期是影响NSCLC患者预后的独立危险因素(P<0.05)。结论:TK1在NSCLC的表达与肿瘤的分化、进展有关,TK1表达有助于对患者预后的评价。

FOXC1在非小细胞肺癌组织中的表达及预后意义

目的:探讨FOXC1在非小细胞肺癌(NSCLC)中的表达水平及其预后意义。方法:将202例NSCLC及63例癌旁肺组织标本制作成组织芯片,采用免疫组织化学SP法检测FOXC1的表达,探讨其表达水平与临床病理特征及预后的关系。结果:NSCLC组织中高表达FOXC1(60.87%)的细胞比率显著高于癌旁肺组织(25.40%)(P<0.001);NSCLC中,FOXC1的表达与TNM分期及淋巴结转移显著相关(P<0.01);Kaplan-Meier生存分析显示FOXC1高表达的NSCLC患者生存期明显低于低表达的患者(P<0.001)。结论:FOXC1在NSCLC中的表达与肿瘤的发生、进展有关,检测FOXC1的表达有助于对患者预后的评价。

Claudin-1在非小细胞肺癌中的表达及意义

目的检测Claudin-1蛋白在非小细胞肺癌(NSCLC)原发癌组织及其淋巴结转移癌组织中的表达,并探讨其与NSCLC各临床病理特征和预后的关系。方法利用组织芯片技术,采用免疫组织化学染色方法检测Claudin-1在1998年1月-2003年12月收集的279例NSCLC原发癌组织及其55例淋巴结转移癌组织、54例癌旁正常肺组织中的表达。运用SPSS 13.00统计软件对相关数据进行统计分析。结果 Claudin-1在279例NSCLC原发癌组织和55例淋巴结转移癌组织中的阳性表达率分别为69.9%和50.9%,在鳞癌和腺癌中的阳性表达率分别为83.7%和55.7%,在高、中分化癌组和低分化癌组中的阳性表达率分别为78.6%和62.7%。Claudin-1在原发癌组织中的阳性表达率高于其淋巴结转移癌组织(P<0.05);在鳞癌中的阳性表达率高于腺癌(P<0.05),且在高、中分化癌组中的阳性表达率高于低分化癌(P<0.05)。Claudin-1阳性表达之NSCLC患者的生存率高于阴性表达者(P<0.05)。结论 Claudin-1在NSCLC中的表达与患者的组织学类型及病理分级有关,且Claudin-1是NSCLC侵袭、转移的抑制因子,并且可能是一个有用的预后因子。